Lapatinib: all 212 studies that test it

Page 1 of 3. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• Dose Escalation of Lapatinib With Paclitaxel in Ovarian CancerCompletedNCT04608409Phase 1Results posted
• Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesTerminatedNCT01934894Phase 2Results posted
• Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerTerminatedNCT01891357Phase 2Results posted
• Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast CancerTerminatedNCT01873833Phase 2Results posted
• Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast CancerTerminatedNCT01868503Phase 2Results posted
• Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerCompletedNCT01827163Phase 2Results posted
• Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric CancerTerminatedNCT01769508Phase 2Results posted
• TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.CompletedNCT01711658Phase 2Results posted
• Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerCompletedNCT01688609Phase 2Results posted
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerCompletedNCT01622868Phase 2Results posted
• Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral SurgeryCompletedNCT01612351Phase 2Results posted
• Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast CancerTerminatedNCT01499160Phase 2Results posted
• Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)TerminatedNCT01395537Phase 1/2Results posted
• Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in BladderTerminatedNCT01382706Phase 2Results posted
• A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc IntervalCompletedNCT01328054Phase 4Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01273610Phase 2Results posted
• A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast CancerTerminatedNCT01272141Phase 2Results posted
• Lapatinib in Stage IV Melanoma With ERBB4 MutationsTerminatedNCT01264081Phase 2Results posted
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedNCT01160211Phase 3Results posted
• Lapatinib in Combination With VinorelbineCompletedNCT01128543Phase 2Results posted
• GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and BiomarkersTerminatedNCT01118975Phase 1/2Results posted
• Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckCompletedNCT01044433Phase 2Results posted
• Extension Study of Lapatinib Plus Herceptin With or Without Endocrine TherapyActive, not recruitingNCT00999804Phase 2Results posted
• Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT00973739Phase 2Results posted
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneTerminatedNCT00968968Phase 3Results posted
• A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)TerminatedNCT00963547Phase 1Results posted
• Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate CancerTerminatedNCT00953576Phase 1/2Results posted
• Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast CancerCompletedNCT00952692Phase 1/2Results posted
• Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyCompletedNCT00939523Phase 2Results posted
• Bevacizumab and Lapatinib in Children With Recurrent or Refractory EpendymomaCompletedNCT00883688Phase 2Results posted
• Lapatinib and Capecitabine for Second Line Treatment of Pancreas CancerTerminatedNCT00881621Phase 2Results posted
• Concentration and Activity of Lapatinib in Vestibular SchwannomasCompletedNCT00863122Early Phase 1Results posted
• Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the BreastTerminatedNCT00857714Not applicableResults posted
• Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ PatientsCompletedNCT00841828Phase 2Results posted
• Dose-Dense Temozolomide + Lapatinib for Recurrent EpendymomaCompletedNCT00826241Phase 2Results posted
• Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerCompletedNCT00820222Phase 3Results posted
• Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone TherapyTerminatedNCT00759642Phase 2Results posted
• Phase II Neoadjuvant in Inflammatory Breast CancerTerminatedNCT00756470Phase 2Results posted
• Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast CancerCompletedNCT00721630Phase 2Results posted
• Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBCCompletedNCT00709761Phase 2Results posted
• Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer SubjectsTerminatedNCT00709618Phase 2Results posted
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibCompletedNCT00680901Phase 3Results posted
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00667251Phase 3Results posted
• Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT00634088Phase 1Results posted
• LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer PatientsCompletedNCT00632489Phase 1Results posted
• Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal AdenocarcinomaCompletedNCT00574171Phase 2Results posted
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerCompletedNCT00558103Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituCompletedNCT00555152Not applicableResults posted
• Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) StudyCompletedNCT00553358Phase 3Results posted
• Lapatinib and Trastuzumab With or Without Endocrine TherapyCompletedNCT00548184Phase 2Results posted
• Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal CancerCompletedNCT00536809Phase 1Results posted
• Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And LapatinibCompletedNCT00526669Phase 2Results posted
• Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.CompletedNCT00524303Phase 2Results posted
• Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From ChinaTerminatedNCT00508274Phase 3Results posted
• Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast CancerTerminatedNCT00496366Phase 2Results posted
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DCompletedNCT00490139Phase 3Results posted
• Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent ChemotherapyTerminatedNCT00490061Phase 2Results posted
• Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric CancerCompletedNCT00486954Phase 3Results posted
• Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast CancerTerminatedNCT00479856Phase 2Results posted
• Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerCompletedNCT00477464Phase 2Results posted
• Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast CancerCompletedNCT00470847Phase 1Results posted
• Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast CancerCompletedNCT00470704Phase 2Results posted
• BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary CancerTerminatedNCT00447122Phase 1Results posted
• Lapatinib and Bevacizumab for Metastatic Breast CancerCompletedNCT00444535Phase 2Results posted
• Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or CarboplatinCompletedNCT00436644Phase 2Results posted
• Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical CancerCompletedNCT00430781Phase 2Results posted
• Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerCompletedNCT00429299Phase 2Results posted
• Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3Results posted
• Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast CancerCompletedNCT00422903Phase 2Results posted
• Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast CancerCompletedNCT00404066Phase 2Results posted
• Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck CancerCompletedNCT00387127Phase 2Results posted
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerCompletedNCT00374322Phase 3Results posted
• A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck CancerCompletedNCT00371566Phase 2Results posted
• Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast CancerCompletedNCT00356811Phase 2Results posted
• Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant GliomaCompletedNCT00350727Phase 2Results posted
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast CancerCompletedNCT00347919Phase 2Results posted
• GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast CancerCompletedNCT00320411Phase 2Results posted
• Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2CompletedNCT00281658Phase 3Results posted
• ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and LapatinibTerminatedNCT00272987Phase 3Results posted
• Lapatinib for Brain Metastases In ErbB2-Positive Breast CancerCompletedNCT00263588Phase 2Results posted
• Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00246753Phase 2Results posted
• Lapatinib in Metastatic Breast Cancer Resistant to Hormone TherapyTerminatedNCT00225758Phase 2Results posted
• Neoadjuvant GW572016 to Treat Breast CancerCompletedNCT00206427Phase 2Results posted
• Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerCompletedNCT00113373Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate CancerCompletedNCT00103194Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00096447Phase 2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2Results posted
• Lapatinib In Chemotherapy-Naive Or Metastatic Breast CancerCompletedNCT00089999Phase 2Results posted
• Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast CancerCompletedNCT00075270Phase 3Results posted
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerCompletedNCT00073528Phase 3Results posted
• A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung CancerTerminatedNCT00073008Phase 2Results posted
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3

← Lapatinib overview